The reduction in Bayer's workforce under turnaround chief executive Bill Anderson has reached around 12,000 – a fall of around 12% since the start of 2024 – and isn't yet completed. On the German ...

Bayer's much-anticipated stem cell therapy for Parkinson's disease is gathering momentum, with dosing in phase 3 trials now underway. The first patient has already been treated with bemdaneprocel, a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Gordon Scott has been an active investor and technical analyst or 20+ years. He is a Chartered Market Technician (CMT). Suzanne is a content marketer, writer, and fact-checker. She holds a Bachelor of ...